Board of Directors

Born in 1973.
Board member since 2012 and Chairman of the Board since 2020. 

Education: Marios Fotiadis holds a B.Sc. from the University of Denver and an MBA from Columbia University. 

Other experience: Marios Fotiadis has more than 20 years of experience from positions within private equity and venture capital in the life science sector, including as a partner of Advent International and TVM Capital. Prior to that, he started his career in private equity and venture capital at SG Capital Partners.

Other current assignments: Marios Fotiadis is Chairman and CEO of Cerus Advisors DMCC and a Board member of Bacara Holdings Ltd, Shoreline BioSciences, Levant Capital, KLARIS S.A., Sente Inc, Opocrin S.p.A. and Plastic Unbound Limited. 

Previous assignments over the past five years: Board member of Mediolanum Farmaceutici Spa, Rossart Ltd, Lexington Holding Assets and Vandel Group JLT. 

Shareholding in the company: 219 668 360 shares via Lexington Holding Assets Ltd (BVI) and Bacara Holdigns Limited, including through closely related parties. 

Independent in relation to the company and its management, but not independent in relation to its major shareholders.

Born in 1960. Board member since 2019. Chairman of the Remuneration Committee. 

Education: Catherine Gilmore-Lawless holds an MBA from McGill University and a BComm from Concordia University. 

Other experience: Catherine Gilmore-Lawless has more than 30 years of experience of neurosurgery. Her experience includes more than 15 years in various senior positions at Elekta Instrument AB, including CEO of Elekta’s US subsidiary, where she played an instrumental role in the US launch of new neuro technology. Her other positions at Elekta included Senior Vice President, Marketing and Vice President, Clinical Intelligence, Neuroscience. 

Other current assignments: Vice President & General Manager, Academics GE HealthCare. 

Previous assignments over the past five years: Catherine Gilmore-Lawless previously served as Senior Vice President of Elekta, Vice President, Strategic Intelligence and Partnerships, Americas at Elekta. Consultant to the International Stereotactic Radiosurgery Society, board member of Clinical Laserthermia Systems. 

Shareholding in the company: – shares. 

Independent in relation to the company and its management and in relation to major shareholders.

Born in 1955. Board member since 2017. Member of the Audit Committee and Remuneration Committee. 

Education: Anita Tollstadius holds an M.Sc. in Pharmacy from Uppsala University and an MBA from the Stockholm School of Economics. 

Other experience: Anita Tollstadius has more than 30 years of experience from global operations in the pharmaceutical industry and has held several senior positions within strategic marketing, communication and organizational development. She has also been CEO for 9 years at a listed company. 

Other current assignments: – 

Previous assignments over the past five years: Board member of MediCheck AB and CEO of ContextVision AB. 

Shareholding in the company: 115,000 shares. 

Independent in relation to the company and its management and in relation to major shareholders.

Born in 1958. Board member since 2015. 

Education: Kleanthis G. Xanthopoulos holds a B.Sc. in biology from Aristotle University, an M.Sc. in microbiology and a Ph.D. in molecular biology from Stockholm University, and was an Associate Professor at Karolinska Institutet in Stockholm, Sweden. 

Other experience: Kleanthis G. Xanthopoulos has more than25 years’ experience from operational positions in the life science sector. He also has extensive experience as an investor in life science companies in the US and Europe and founded four life science companies before joining IRRAS, of which two have been listed on Nasdaq (Anadys Pharmaceuticals, Inc. which was acquired by F. Hoffmann-LaRoche Inc. in 2011, and Regulus Therapeutics Inc). 

Other current assignments: Board member of Sente Inc., Connect Biopharma, Shoreline Biosciences and of Helios Inc. 

Previous assignments over the past five years: Chairman of the Board of ApricusBiosciences and Bioniz, Board member ofLDO spa, Managing General Partner at Cerus Advisors and President and CEO of Regulus Therapeutics. 

Shareholding in the company: 13,014,870 shares and 1,490,277 personnel options. 

Not independent in relation to the company its management or its major shareholders.